drugset / Trial / NCT04634669

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

NCT04634669

Phase 2 Terminated 181 enrolled Axsome Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is a multi-center, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in subjects with major depressive disorder with prior treatment failures

Timeline

Start
2020-09-23
Primary completion
2022-02-18
Completion
2022-03-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 105 mg
Subject Dextromethorphan Unknown 45 mg